Влияние недавних изменений в GVP ЕАЭС
January 21, 2025
Pharmacovigilance Inspections in the EAEU: Key Changes and Preparation
In 2024, changes to pharmacovigilance requirements within the EAEU are expected. According to the project of changes of the rules presented in the Decision of the Eurasian Economic Commission’s Council of 3 November 2016 № 83 "On Approval of the Rules for Pharmacovigilance Inspections", an important aspect involves additional requirements for pharmacovigilance inspections. These additions apply to both scheduled and unscheduled inspections focused on ensuring compliance with applicable requirements of pharmacovigilance.
The additions to the pharmacovigilance system inspection rules emphasize the possibility of inspecting Marketing Authorisation Holders (MAHs) at any time. Important to know:
- Inspections can be conducted without prior notice in exceptional cases, for example, when significant risks to public health are identified
- Routine practice includes prior notification, usually 45 days before the planned inspection
- The notification period may vary depending on the situation and the need for an urgent assessment.
Key Steps and Processes to Prepare for a Pharmacovigilance System Inspection
Preparing for a pharmacovigilance system audit is a key step to ensure compliance with applicable regulations and a high level of pharmaceutical standards. This process requires careful preparation and attention to detail to ensure the effectiveness and completeness of the inspection.
Preparation for a pharmacovigilance system inspection includes the following steps:
1. Review of Documents
Inspectors examine the provided documents from the inspected organization, describing the pharmacovigilance system, including data on previous inspections and their results.
2. Scope Determination of the Inspection
Based on the type and objectives of the inspection and the reviewed documents, inspectors determine which components of the pharmacovigilance system will be inspected.
3. Development of the Inspection Program
Inspectors approve a program that includes the objectives and scope of the inspection, the division of responsibilities among inspectors, the date and location of the inspection, and a list of documents and resources for the assessment.
4. Logistical and Organizational Preparations
The format of the inspection (online or offline) is approved, and the inspected organization shall be notified of all upcoming activities and requirements, including the possible use of remote communication tools.
During the pharmacovigilance system inspection, various aspects are assessed, including compliance with documentation, operation of computerized systems, interviews with staff, and analysis of internal and external correspondence. The inspection may be adapted according to factors discovered or specific circumstances, including changes in the scope or focus of the inspection.
All observations and results of the inspection are carefully documented and identified non-compliances are categorized and discussed at the final meeting between inspectors and representatives of the inspected organization. Following the inspection, a corrective and preventive actions plan (CAPA) must be compiled within 30 working days of receiving the report.
How to Prepare for a Pharmacovigilance Inspection for Successful Completion?
Inpharmatis offers comprehensive support in preparing for a pharmacovigilance inspection, including:
1. Preliminary Audit of the Pharmacovigilance System
Inpharmatis experts will conduct a detailed pre-audit of your pharmacovigilance system to identify potential vulnerabilities and areas for improvement.
2. Training Interviews with Staff
Conducting interviews with your employees to enhance their readiness for real inspectors' questions.
3. Preparation for Logistical and Organisational Aspects
Provide consultations on all logistics and organizational aspects to ensure the successful result of the inspection.
4. Preparation of Recommendations Based on the Audit Results
Organisation and optimisation of pharmacovigilance documentation and processes, ensuring their compliance with current regulatory requirements.
* Also, Inpharmatis specialists propose expert support of CAPA plan preparation.
The result of your partnership with Inpharmatis is to ensure inspection readiness, minimize risk, and increase your chances of passing an inspection.
Request a consultation now at info@inpharmatis.com.
Article author
Hanna Balyka,
Pharmacovigilance Manager
Inpharmatis


Impact of Recent Changes in EAEU GVP
January 21, 2025
Новые правила оплаты регистрации лекарственных средств и медицинских изделий в Узбекистане
December 03, 2024
New Payment Rules for Medicines and Medical Device Registration in Uzbekistan
December 03, 2024
Inpharmatis открыла юридическое лицо в Узбекистане
November 28, 2024
Inpharmatis Opens an LLC Legal Entity in Uzbekistan
November 28, 2024
Полина Домбуре, генеральный директор Inpharmatis Group, выступит спикером на вебинаре, организованном TOPRA
October 16, 2024
Dr. Polina Dombure to Speak at TOPRA Webinar "Navigating Regulatory Changes in Moldova and Ukraine"
October 16, 2024
Полина Домбуре, генеральный директор Inpharmatis Group, примет участие в CPHI Milan 8-10 октября 2024
September 25, 2024
Dr. Polina Dombure, CEO of Inpharmatis Group, will be attending CPHI Milan in 8-10 October 2024
September 25, 2024